• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

How Dr O’Shaughnessy Balances Clinical Benefits and Cost Considerations when selecting a CDK4/6 Inhibitor

Opinion
Video

Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.

Related Videos
5 experts are featured in this series.
Dawn Klemow, MD, assistant clinical professor, The University of Texas Southwestern Medical Center
5 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.